vibegron   Click here for help

GtoPdb Ligand ID: 10100

Synonyms: compound 7 [PMID: 26709102] | Gemtesa® | KRP-114V [1] | MK-4618 | MK4618
Approved drug
vibegron is an approved drug (FDA (2020))
Compound class: Synthetic organic
Comment: Vibegron (MK-4618) is a potent and selective β3 adrenoceptor agonist that was developed by Merck as a pharmacological modulator for the management of overactive bladder [1-2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 7
Topological polar surface area 96.25
Molecular weight 444.22
XLogP 2.47
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES O=C(C1CCc2n1c(=O)ccn2)Nc1ccc(cc1)CC1CCC(N1)C(c1ccccc1)O
Isomeric SMILES O=C([C@@H]1CCc2n1c(=O)ccn2)Nc1ccc(cc1)C[C@@H]1CC[C@@H](N1)[C@@H](c1ccccc1)O
InChI InChI=1S/C26H28N4O3/c31-24-14-15-27-23-13-12-22(30(23)24)26(33)29-19-8-6-17(7-9-19)16-20-10-11-21(28-20)25(32)18-4-2-1-3-5-18/h1-9,14-15,20-22,25,28,32H,10-13,16H2,(H,29,33)/t20-,21+,22-,25+/m0/s1
No information available.
Summary of Clinical Use Click here for help
The efficacy of vibegron (MK-4618) in humans was evaluated in Phase 3 clinical trials in patients with overactive bladder (OAB; see NCT03583372 and NCT03492281). In both of these studies vibegron was directly compared to tolterodine tartrate which is a non-selective murcarinic receptor antagonist that is used to manage urinary incontinence.
In December 2020, the FDA approved vibegron as a once-daily therapeutic for OAB.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
In vivo (in monkeys), vibegron increases bladder capacity, decreases micturition pressure, and increases bladder compliance [1]
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03492281 A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) Phase 3 Interventional Urovant Sciences GmbH
NCT03583372 An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB). Phase 3 Interventional Urovant Sciences GmbH